Ren Wenwei, Luan Xiaoqian, Zhang Jie, Gutteea Priyanka, Cai Yan, Zhao Jiyun, Gu Yingying, Wu Chaowen, Su Hang, Tao Jingyan, Xie Ying, Lv Dezhao, Feng Liang, He Jincai
Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.
Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200000, China.
J Affect Disord. 2017 Oct 15;221:165-171. doi: 10.1016/j.jad.2017.06.017. Epub 2017 Jun 14.
Depression symptoms is highly comorbid with methamphetamine (METH) dependence. Except for the role in the pathophysiology of depression symptoms, brain-derived neurotrophic factor (BDNF) is also involved in the METH dependence. The present study aims to explore whether BDNF plays a role in the development of depression symptoms during METH withdrawal.
We recruited 179 patients with METH dependence who were followed up for two weeks. Ultimately, 131 (73.2%) patients finished the follow-up. Besides, 90 healthy controls were also recruited. Serum BDNF levels were measured by DuoSet ELISA Development System upon admission. The short form (13 items) of the Beck Depression Inventory (BDI) and Amphetamine Withdrawal Questionnaire (AWQ) were used to measure the depression and withdrawal symptoms. Patients with BDI score ≥ 8 were identified to have depression symptoms.
Of the 131 patients, 64 (48.9%) were identified to have depression symptoms at the two-week endpoint. Patients with depression symptoms showed significantly lower BDNF levels than those with no depression symptoms. Serum BDNF levels (≤ 1251.0pg/ml) were independently associated with the development of depression symptoms during METH withdrawal (OR = 3.50, 95% CI, 1.14-10.73, p = 0.028).
BDNF levels were tested in serum but not in brain and the baseline BDI and AWQ scores between the depression and non-depression groups were not matched. Besides, the follow-up time was relatively short.
Our study demonstrated that patients with serum BDNF levels ≤ 1251.0pg/ml had higher risk of depression symptoms during METH withdrawal.
抑郁症状与甲基苯丙胺（METH）依赖高度共病。脑源性神经营养因子（BDNF）除了在抑郁症状的病理生理学中起作用外，还参与METH依赖。本研究旨在探讨BDNF在METH戒断期间抑郁症状发展中是否起作用。
我们招募了179例METH依赖患者，随访两周。最终，131例（73.2%）患者完成随访。此外，还招募了90名健康对照者。入院时采用DuoSet ELISA检测系统测量血清BDNF水平。采用贝克抑郁量表（BDI）简版（13项）和苯丙胺戒断问卷（AWQ）测量抑郁和戒断症状。BDI评分≥8分的患者被确定为有抑郁症状。
在131例患者中，64例（48.9%）在两周终点时被确定为有抑郁症状。有抑郁症状的患者BDNF水平显著低于无抑郁症状的患者。血清BDNF水平（≤1251.0pg/ml）与METH戒断期间抑郁症状的发展独立相关（OR = 3.50，95%CI，1.14 - 10.73，p = 0.028）。
BDNF水平在血清中检测，而非在脑中检测，且抑郁组和非抑郁组之间的基线BDI和AWQ评分不匹配。此外，随访时间相对较短。
我们的研究表明，血清BDNF水平≤1251.0pg/ml的患者在METH戒断期间出现抑郁症状的风险更高。
